In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > BUSINESS
BUSINESS
- Nomura Securities Report Says Takeda’s TAK-875 Hoped to Become Blockbuster
March 6, 2012
- Pfizer to Outsource Clinical Trials in Japan to 2 CROs from April
March 6, 2012
- Share of Aricept Generic to Increase by Some 20% in Future: Eisai Senior Vice President Naoe
March 5, 2012
- Daiichi Sankyo, GSK Agree to Set Up Joint Venture in Vaccine Business
March 5, 2012
- Novartis Most Admired Pharmaceutical Company in IAL Survey; Will “MR quality” Be Its Achilles’ Heel?
March 5, 2012
- ReproCELL to Change Model of Drug Discovery by Launching World’s 1st iPS Cell-derived Hepatocytes
March 5, 2012
- Sanofi-aventis Nichi-Iko Withholds NHI Price Listing of Authorized Allegra Generic in June
March 2, 2012
- Eisai President Naito Approves of Government Measures, Saying Japan’s Positioning “Improving Greatly”
March 2, 2012
- Pfizer Files Lawsuit Against Sandoz for Generic Lipitor, Sandoz to Contest Action
March 2, 2012
- Carna Biosciences Aiming to Out-License First Products to Megapharma in 2012 “if Possible”
March 2, 2012
- Medipal Group to Determine Profitability with Each Customer: Next President Shuichi Watanabe
March 2, 2012
- SBI to Enter Pharmaceutical Business Through Subsidiary, Considering Domestic Plant
March 1, 2012
- Takeda Initiates PIII Clinical Trials of Leuplin 6-Month Depot Formulation in Japan
March 1, 2012
- Takeda to Issue Straight Bonds for the First Time in 25 Years to Cover Nycomed Acquisition
March 1, 2012
- Takeda to Operate Global Vaccine Business, Aiming to Join Top 5 in 10 Years
March 1, 2012
- DSP to Acquire Boston Biomedical, US Bioventure Specializing in Oncology
March 1, 2012
- Nippon Kayaku Applies for Vascular Embolizing Agent NK939
March 1, 2012
- “It Is Time for Ranbaxy to Regain Brilliancy”: Daiichi Sankyo
February 29, 2012
- MTPC to Reorganize Product Marketing Dept. Aiming at Early Market Penetration of New Products
February 29, 2012
- Pfizer Japan to Set Up Rare Disease Division
February 29, 2012
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…